202 related articles for article (PubMed ID: 36976507)
21. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
[TBL] [Abstract][Full Text] [Related]
22. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
[TBL] [Abstract][Full Text] [Related]
23. Identification of High-affinity Small Molecules Targeting Gamma Secretase for the Treatment of Alzheimer's Disease.
Ali MA; Vuree S; Goud H; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1173-1187. PubMed ID: 31244427
[TBL] [Abstract][Full Text] [Related]
24. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
[TBL] [Abstract][Full Text] [Related]
25. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
26. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
[TBL] [Abstract][Full Text] [Related]
27. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Yoshida Y; Ozawa T; Yao TW; Shen W; Brown D; Parsa AT; Raizer JJ; Cheng SY; Stegh AH; Mazar AP; Giles FJ; Sarkaria JN; Butowski N; Nicolaides T; James CD
Mol Cancer Ther; 2014 Dec; 13(12):2919-29. PubMed ID: 25313012
[TBL] [Abstract][Full Text] [Related]
28. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.
Kwatra MM
Curr Cancer Drug Targets; 2017; 17(3):290-296. PubMed ID: 28029074
[TBL] [Abstract][Full Text] [Related]
29. Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC).
Adhikary R; Khandelwal R; Hussain T; Nayarisseri A; Singh SK
Curr Comput Aided Drug Des; 2021; 17(3):387-401. PubMed ID: 32364080
[TBL] [Abstract][Full Text] [Related]
30. Virtual Screening of IL-6 Inhibitors for Idiopathic Arthritis.
Shukla P; Khandelwal R; Sharma D; Dhar A; Nayarisseri A; Singh SK
Bioinformation; 2019; 15(2):121-130. PubMed ID: 31435158
[TBL] [Abstract][Full Text] [Related]
31. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
[TBL] [Abstract][Full Text] [Related]
32. Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study.
Hermawan A; Wulandari F; Hanif N; Utomo RY; Jenie RI; Ikawati M; Tafrihani AS
Sci Rep; 2022 Aug; 12(1):13928. PubMed ID: 35977996
[TBL] [Abstract][Full Text] [Related]
33. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
34. FHL2 interacts with EGFR to promote glioblastoma growth.
Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
[TBL] [Abstract][Full Text] [Related]
35. Identification of upregulated genes in glioblastoma and glioblastoma cancer stem cells using bioinformatics analysis.
Caglar HO; Duzgun Z
Gene; 2023 Jan; 848():146895. PubMed ID: 36122609
[TBL] [Abstract][Full Text] [Related]
36. Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening.
Ornnork N; Kiriwan D; Lirdprapamongkol K; Choowongkomon K; Svasti J; Eurtivong C
J Mol Graph Model; 2020 Sep; 99():107639. PubMed ID: 32534372
[TBL] [Abstract][Full Text] [Related]
37. A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.
Qureshi S; Khandelwal R; Madhavi M; Khurana N; Gupta N; Choudhary SK; Suresh RA; Hazarika L; Srija CD; Sharma K; Hindala MR; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2021; 21(9):790-818. PubMed ID: 33463471
[TBL] [Abstract][Full Text] [Related]
38. Computer-aided Drug Designing for the Identification of High-Affinity Small Molecule Targeting CD20 for the Clinical Treatment of Chronic Lymphocytic Leukemia (CLL).
Sinha K; Majhi M; Thakur G; Patidar K; Sweta J; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(29):2527-2542. PubMed ID: 30526461
[TBL] [Abstract][Full Text] [Related]
39. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
40. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
